Rita A. Sakr

TL;DR: A comprehensive genetic analysis of two independent cohorts of metastatic ER-positive breast tumors and identified mutations in ESR1 affecting the ligand-binding domain (LBD) in 14 of 80 cases that implicate LBD-mutant forms of ER in mediating clinical resistance to hormonal therapy and suggest that more potent ER antagonists may be of substantial therapeutic benefit.

TL;DR: Pathologic characteristics of BRCA1 and BRCa2 tumors may be useful for improving risk-prediction algorithms and informing clinical strategies for screening and prophylaxis.

TL;DR: Data suggest that increasing use of CPM is not associated with increased recognition of patients at high risk for CBC, and treatment factors, such as immediate reconstruction, preoperative MRI, and unsuccessful attempts at breast conservation, are associated withincreased rates of C PM.

TL;DR: The clinical challenge posed by DCIS, the contribution of the microenvironment and genetic aberrations to the progression from in situ to invasive breast cancer, the emerging evidence of the impact of intra‐tumor genetic heterogeneity on this process, and strategies to combat this heterogeneity are reviewed.

TL;DR: Functional studies demonstrated that this kinase-activating alteration likely constitutes a driver of PLGA.